Skip to main content

Table 1 Patient characteristics of minocycline and doxycycline users and nonusers

From: Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects

  Initiated MC/DC (n = 480) Never used MC/DC (n = 14,309) P value
Age (years) 58.35 (11.60) 59.76 (13.28) 0.021
Male sex (%) 20.83 22.23 0.469
Rheumatoid arthritis duration (years) 14.77 (10.92) 13.70 (11.05) 0.036
Education (years) (0 to 17) 13.70 (2.32) 13.52 (2.33) 0.106
Caucasian, non-Hispanic (%) 93.68 89.72 0.005
Income (US$) 46,698 (28,088) 46,309 (29,352) 0.775
Semi-annual costs (US$) 6,007 (10,635) 5,685 (7,835) 0.406
Semi-annual drug costs (US$) 4,073 (8,522) 3,826 (6,528) 0.098
Insurance (%)    0.044
   Private 29.17 27.26  
   Health maintenance organization 11.25 8.64  
   Medicare 41.67 47.10  
   Preferred provider organization 10.00 9.27  
   Medicaid 4.79 5.77  
   No insurance 3.13 1.95  
Lifetime DMARDs 2.90 (1.83) 2.13 (1.54) < 0.001
Lifetime DMARDs and biologics 3.30 (2.10) 2.52 (1.81) < 0.001
Prednisone (%) 40.08 35.34 0.033
Methotrexate (%) 49.48 50.48 0.667
Comorbidity index (0 to 9) 1.68 (1.46) 1.59 (1.48) 0.193
Health Assessment Questionnaire (0 to 3) 1.06 (0.71) 1.04 (0.73) 0.474
Physical component summary score (0 to 100) 35.03 (11.17) 36.39 (11.09) 0.008
Mental component summary score (0 to 100) 50.02 (11.30) 49.11 (11.49) 0.086
Patient global (0 to 10) 3.47 (2.50) 3.50 (2.53) 0.784
Pain (0 to 10) 3.92 (2.82) 3.83 (2.79) 0.506
Patient Activity Scale (0 to 10) 3.64 (2.27) 3.60 (2.24) 0.666
  1. Data presented as mean (standard deviation). DC, doxycycline; DMARD, disease-modifying anti-rheumatic drug; MC, minocycline.